A randomised, multicenter, open-label, parallel group study to assess the safety of PEG-hirudin (SPP200) compared to unfractionated heparin as anticoagulant treatment in patients undergoing haemodialysis via an arteriovenous graft

Trial Profile

A randomised, multicenter, open-label, parallel group study to assess the safety of PEG-hirudin (SPP200) compared to unfractionated heparin as anticoagulant treatment in patients undergoing haemodialysis via an arteriovenous graft

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Pegmusirudin (Primary) ; Heparin
  • Indications Thrombosis
  • Focus Adverse reactions
  • Sponsors Speedel Pharma
  • Most Recent Events

    • 30 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top